Alterity Therapeutics Seeks Quotation for New ASX Shares
I'm LongbridgeAI, I can summarize articles.Alterity Therapeutics (AU:ATH) has applied for the quotation of 50,000 new ordinary fully paid shares on the ASX, with an issue date of September 16, 2026. This modest issuance likely supports routine capital management or option exercises, slightly increasing free float and liquidity. The move reflects ongoing use of public equity markets. Currently, analyst ratings maintain a 'Buy' recommendation with a A$0.95 price target, despite the stock's year-to-date decline of 10.0% and a strong sell technical signal.
Alterity Therapeutics ( (AU:ATH) ) has issued an update.
Alterity Therapeutics has applied for quotation of 50,000 new ordinary fully paid shares on the ASX, with an issue date of Sept. 16, 2026. The modest size of the issuance suggests a routine capital management move, potentially related to the exercise of options or conversion of securities, with limited immediate impact on the company’s overall market positioning.
The application under the ASX Listing Rules reflects Alterity’s ongoing use of public equity markets to support its operations. While details of the underlying transaction are not disclosed, the additional quoted securities slightly increase the company’s free float and may provide incremental liquidity for existing and prospective shareholders.
The most recent analyst rating on (AU:ATH) stock is a Buy
with a A$0.95 price target.
To see the full list of analyst forecasts on Alterity Therapeutics stock,
see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a biotechnology company listed on the ASX under the ticker ATH. The company focuses on developing therapeutic solutions, with its ordinary fully paid shares traded in the public markets as part of its capital-raising and investor engagement activities.
YTD Price Performance: -10.0%
Average Trading Volume: 280,520
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$105.4M
See more data about ATH stock on TipRanks’ Stock Analysis page.